Morgan Stanley analyst Terence Flynn has maintained their bullish stance on GILD stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Terence Flynn has given his Buy rating due to a combination of factors surrounding Gilead Sciences’ strategic positioning and future prospects. A key element influencing this decision is the recent settlement that extends the loss of exclusivity for Biktarvy, a major HIV treatment, to 2036. This extension provides Gilead with additional time to implement its lifecycle management strategy, which is crucial for maintaining its leadership in the HIV treatment market.
Furthermore, Gilead’s robust pipeline of next-generation HIV treatments, which includes longer-acting oral and injectable regimens, positions the company for sustained growth. The potential for multiple approvals of these new treatments by 2033, as highlighted by management, underscores the company’s commitment to innovation. This strategic foresight and the extended patent protection for Biktarvy contribute to Flynn’s optimistic outlook on Gilead’s stock, justifying the Buy rating.
According to TipRanks, Flynn is a 4-star analyst with an average return of 4.5% and a 56.55% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Gilead Sciences, BioNTech SE, and Bristol-Myers Squibb.
In another report released yesterday, Needham also maintained a Buy rating on the stock with a $133.00 price target.